Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL. clonoSEQ is the only DLBCL MRD assay available for clinical u ...

In CLL, we believe we're in the middle of a once ... First, AMPLIFY did not show a deep MRD response. Actually, only 34% of AV patients reached MRD negativity, which was both statistically ...

To him, the company’s potential in chronic lymphocytic leukemia is akin to two other ... combo’s disappointing performance on minimal residual disease, which is a deep response measurement ...

“2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements ... decisions in patients with MCL, CLL, MM and ALL Studies show depth of response ...

The results could herald a step change in treating CLL, which current treatments ... as tested by flow cytometry and/or analysis for minimal residual disease (MRD), which measures residual ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL. Venetoclax-containing regimens demonstrated superior ...

Concerning overall survival and disease control, no disadvantage compared to other populations of CLL patients receiving immuno-chemotherapy could be detected, as a mortality rate of 4% and median ...

A-CLL is distinguished by its intermediate behavior between indolent ... achieving a partial response (PR) with some residual lymph nodes measuring 2 cm and detectable minimal residual disease (MRD4, ...